HerpHu-mAb - Effective therapeutic antibody against Herpes Simplex Virus Infections
|
|
- Godwin Jessie Wells
- 5 years ago
- Views:
Transcription
1 HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections Prof. Dr. Michael Roggendorf Institute of Virology University Duisburg-Essen Germany
2 HV-1 / HV-2: associated diseases Keratitis, Retinitis (Eye) Herpes simplex encephalitis (Brain) Herpes labialis (HV-1) Disseminated Herpes (Lung, Liver) Eczema Herpes (kin) Herpes genitalis (HV-2) transka R, J Clin Virol Morfin F, J Clin Virol Doerr, 2010 Folie Medizinische 2 Virologie Epidemiology: Worldwide, 90% of people are seropositive for one or both virus types. Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 2
3 HV-1 / HV-2: therapy and resistance Antivirals: Aciclovir Foscarnet Cidofovir Nucleoside analogue Pyrophosphate analogue Nucleoside analogue Drug resistance: % normal population 4 7% AID/HIV-patients, chemotherapy recipients, eye infections 14 27% patients after stem cell transplantation Multiresistant strains (ACV, PFA, CDV) Alternatives:? Monoclonal antibody HerpHu-mAb Humanized HV-1/2 gb-targeting antibody Folie 3 transka R, J Clin Virol. 2005; Morfin F, J Clin Virol Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 3
4 HerpHu-mAb human Anti-HV-Ab HerpHu-mAb HerpHu-mAb: Inhibition of the cell-to-cell spread Phase contrast HV-1 Anti-human-Fc No comparable antibody generated in humans (or not isolated so far)! Folie 4 Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 4
5 HV: Disseminated and severe diseases Herpes implex Genitalis 1 : Epidemiology: estimated incidences in U and Europe range from 5 to 24 per 100 people per year Herpes implex Encephalitis 2 : Epidemiology: approx. 1 per 250,000 to 500,000 individuals per year Mortality: untreated about 70%, with Acyclovir about 28% Morbidity: 62% of survivors having some form of neurologic debility only 2.5% return to normal neurologic function Ocular HV diseases: Keratitis 3 and Retinitis: Epidemiology: estimated number of new cases of severe monocular visual impairment or blindness each year, global incidence of HV-induced ocular disease is roughly 1.5 million 1 Malkin JE, Herpes James H, Antiviral Res Folie 3 Farooq, 5 AV; hukla, D, urvey of ophthalmology 2012 Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 5
6 Immunsuppression: Disseminated disease Herpes simplex encephalitis (Brain) Disseminated Herpes (Lung, Liver) Herpes genitalis (HV-1/2) Folie 6 Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 6
7 Immunosuppression: Generalized HV (lethal) Model: NOD/CID mice Infection: vaginal, 1 x 10 6 TCID 50 Virus: HV-1 R10.2 (resistance: ACV, PFA, CDV) ACV: HerpHu-mAb: 50 mg/kg body weight; each 12h 24h, 40h und 56h post infection (300 µg/kg bw i.v.) Folie 7 1 Krawczyk et. al., PNA Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 7
8 Ocular HV diseases: Keratitis Keratitis (Eye) Folie 8 Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 8
9 Ocular HV diseases: Retinitis Retinitis (Eye) Mice with acute retinal necrosis [%] p=0.09 p= ** *** *** *** *** PB ACV P PEP T Topical P PEP Controls mab 2c mab hu2c Folie 9 Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 9
10 ummary Antiviral efficacy of HerpHu-mAb towards HV-1/2 ( including drug resistant clinical isolates) was demonstrated in cell culture and animal models Protection of highly immunodeficient NOD/CID mice from generalized, lethal infections Highly effective prevention of HV-mediated Keratitis and Retinitis Promising compound to fight severe and/or drug resistant HV infections Patent applications filed in U, Europe, Canada, China, Japan, India and Brasilia Market volume (estimated): > 500 mio U-$/year Folie 10 Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 10
11 Perspectives und future projects 1.PhaseI clinical trials 2.Charaterization of the B Cell epitope of this HerpHu-mAb 3.Development of a HV1/2 Vaccine containing the relevant B Cell epitopes Universitätsklinikum Bonn Institut für Virologie Anna-Maria Eis-Hübinger Eduard chneweis + Universitätsklinikum Essen Institut für Virologie Adalbert Krawczyk Michael Roggendorf University College London Department of Biochemistry and Molecular Biology Andrew C.R. Martin Universität Tübingen Abteilung für Immunologie Ludger Große-Hovest Nationales Centrum für Tumorerkrankungen Heidelberg Michaela Arndt Jürgen Krauss University of Pennsylvania Department of Microbiology Florent Bender, Ph. D Folie 11 Prof. Dr. Michael Roggendorf HerpHu-mAb - Effective therapeutic antibody against Herpes implex Virus Infections 11
HSV DNA replication. Herpesvirus Latency. Latency and Chemotherapy. Human Herpesviruses - subtypes. Acyclovir (acycloguanosine) {Zovirax}
Human Herpesviruses - subtypes Herpes Simplex I (HSVI) - herpes labialis (cold sores) herpes keratitis (eye infections) HSVII - herpes genitalis (genital herpes) Varicella Zoster virus (VZV) Chicken pox
More informationHerpes Simplex Viruses: Disease Burden. Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012
Herpes Simplex Viruses: Disease Burden Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012 Mucocutaneous HSV Infections Life-Threatening HSV Diseases
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationSample Selection- Vignettes
Sample Selection- Vignettes Rangaraj Selvarangan, BVSc, PhD, D(ABMM) Professor, UMKC School of Medicine Director, Microbiology, Virology and Molecular Infectious Diseases Laboratory Director, Laboratory
More informationShingles prophylaxis acyclovir
Shingles prophylaxis acyclovir Search 27-2-2018 Detailed Acyclovir dosage information for adults and TEENren. Includes dosages for Herpes Simplex - Suppression, Herpes Simplex Labialis, Herpes Zoster.
More informationAntiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiviral Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Viruses Viruses are the smallest infective agents, consisting of nucleic acid (DNA or RNA) enclosed
More informationAntiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiviral Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Viruses Viruses are the smallest infective agents, consisting of nucleic acid (DNA or RNA) enclosed
More informationBarry Slobedman. University of Sydney. Viruses in May 11 th May, 2013
Barry Slobedman University of Sydney Viruses in May 11 th May, 2013 Outline Human cytomegalovirus (CMV) impact on the community Three phases of infection Focus on the dormant (latent) phase of infection
More informationAPPENDIX II: Corneal Penetration and Median Effective Dose of Antiviral Agents
APPENDIX II: Corneal Penetration and Median Effective Dose of Antiviral Agents Median Effective Dose (ED50) The median effective dose is a statistically derived dose of drug expected to produce a certain
More informationHC WAINWRIGHT 20 TH ANNUAL GLOBAL INVESTMENT CONFERENCE GARRETT NICHOLS, MD, MS CHIEF MEDICAL OFFICER SEPTEMBER 6, 2018
HC WAINWRIGHT 20 TH ANNUAL GLOBAL INVESTMENT CONFERENCE GARRETT NICHOLS, MD, MS CHIEF MEDICAL OFFICER SEPTEMBER 6, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain
More informationHerpesvirus infections in pregnancy
Herpesvirus infections in pregnancy Dr. med. Daniela Huzly Institute of Virology University Medical Center Freiburg, Germany Herpes simplex virus 1+2 Risk in pregnancy and at birth Primary infection in
More information1Q2018 EARNINGS CALL MAY 7, 2018
1Q2018 EARNINGS CALL MAY 7, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities
More informationCMV in kidney Transplant recipient: A diagnostic and therapeutic Dilema
CMV in kidney Transplant recipient: A diagnostic and therapeutic Dilema By Mohamed A. Sobh MD,FACP Professor and head of Nephrology Urology and Nephrology Center Mansoura - Egypt Cytomegalovirus Virology
More informationViruses and cancer: Should we be more afraid?
Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? During the past 30 years it has become exceedingly clear that several viruses play significant roles in the development
More informationDisseminated shingles acyclovir
Disseminated shingles acyclovir The Borg System is 100 % Disseminated shingles acyclovir Two developed disseminated herpes zoster, one developed cytomegalovirus. Reduced response to acyclovir,. Disseminated
More informationNew proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus
New proposals for WHO International Standards for Human Herpesvirus 6 and Adenovirus Jacqueline Fryer Division of Virology, NIBSC National Institute for Biological Standards and Control Assuring the quality
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationResponse to Acyclovir in Immunocompetent and Immunocompromised herpes genitalis patients
International Journal of Sciences & Applied Research www.ijsar.in Response to Acyclovir in Immunocompetent and Immunocompromised herpes genitalis patients Duggirala S.S. Srinivas Prasad*, T.V. Narasimha
More informationRecommendations for VZV management in. Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman
Recommendations for VZV management in patients Cas cliniques with leukemia Dan Engelhard, Pierre Reusser, Rafael de la Camara, Hermann Einsele, Jan Styczynski, Kate Ward, Per Ljungman Introduction Acute
More informationSteps in viral replication (I)
Antiviral agents Steps in viral replication (I) Recognition of the target cell Attachment Penetration Uncoating Macromolecular synthesis Assembly of virus Buddding of enveloped viruses Release of virus
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationHerpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
CLINICAL MICROBIOLOGY REVIEWS, Jan. 2003, p. 114 128 Vol. 16, No. 1 0893-8512/03/$08.00 0 DOI: 10.1128/CMR.16.1.114 128.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Herpes
More informationDiagnosis of CMV infection UPDATE ECIL
UPDATE ECIL-4 2011 Recommendations for CMV and HHV-6 management in patients with hematological diseases Per Ljungman, Rafael de la Camara, Hermann Einsele, Dan Engelhard, Pierre Reusser, Jan Styczynski,
More informationmodified dye uptake assay including formazan test EC 90 not tested plaque reduction assay
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationPRODUCT INFORMATION H 2
PRODUCT IFORMATIO ZOVIRAX COLD SORE CREAM APPROVED AME: Aciclovir COMPOSITIO: Aciclovir 5% w/w. DESCRIPTIO: Aciclovir is a synthetic acyclic purine nucleoside analogue. Its chemical name is 9-((2-hydroxyethoxy)methyl)guanine.
More informationSummary of the risk management plan (RMP) for Imlygic (talimogene laherparepvec)
EMA/713818/2015 Summary of the risk management plan (RMP) for Imlygic ( laherparepvec) This is a summary of the risk management plan (RMP) for Imlygic, which details the measures to be taken in order to
More informationAcute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient
CM&R Rapid Release. Published online ahead of print September 20, 2012 as Aperture Acute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient Elizabeth
More informationSubunit adjuvanted zoster vaccine: why the fuss?
Subunit adjuvanted zoster vaccine: why the fuss? Soren Gantt, MD PhD MPH Pediatric Infectious Diseases Vaccine Evaluation Center BC Children s Hospital University of British Columbia Disclosures Research
More informationCytomegalovirus A common virus causing serious disease
Cytomegalovirus A common virus causing serious disease THEME: Systemic viral infections BACKGROUND Human cytomegalovirus (CMV) is a herpes virus that causes severe illness and death in people whose immune
More informationSMALLPOX QUESTIONS AND ANSWERS: The Disease and the Vaccine
SMALLPOX QUESTIONS AND ANSWERS: The Disease and the Vaccine In General What should I know about smallpox? Smallpox is an acute, contagious, and sometimes fatal disease caused by the variola virus (an orthopoxvirus),
More informationDedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology
Dedicated to Preventing and Treating Life-Threatening Viral Infections Randall Lanier Vice President, Biology Adenovirus: Epidemiology and Treatment Options Allogeneic hematopoietic cell transplant (allo
More informationTomoyuki Shiota, Ichiro Kurane, Shigeru Morikawa, and Masayuki Saijo*
Jpn. J. Infect. Dis., 64, 121-126, 2011 Original Article Long-Term Observation of Herpes Simplex Virus Type 1 (HSV-1) Infection in a Child with Wiskott-Aldrich Syndrome and a Possible Reactivation Mechanism
More informationEmerging CMV Resistance Profile for CMX001
Emerging CMV Resistance Profile for CMX001 International Conference on Antiviral Research May 15, 2013 Randall Lanier, PhD Forward Looking Statements These slides and the accompanying oral presentation
More informationGenotyping of Cytomegalovirus (or Herpes Simplex Virus) for Ganciclovir (Aciclovir) and Foscarnet Resistance (code 40514) Notice of Assessment
Genotyping of Cytomegalovirus (or Herpes Simple Virus) for Ganciclovir (Aciclovir) and Foscarnet Resistance (code 40514) Notice of Assessment June 2013 DISCLAIMER: This document was originally drafted
More informationInfectious Diseases. Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 )
Infectious Diseases Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 ) The Challenge of Infectious Disease Infectious disease represents the greatest challenge to mankind
More informationAntiviral Chemotherapy
12 Antiviral Chemotherapy Why antiviral drugs? Vaccines have provided considerable success in preventing viral diseases; However, they have modest or often no therapeutic effect for individuals who are
More informationThe chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:
Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram
More informationAcyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B
Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis Little S E, Caughey A B Record Status This is a critical abstract of an economic evaluation
More informationInfections in immunocompromised host
Infections in immunocompromised host Immunodeficiencies Primary immunodeficiencies Neutrophil defect Humoral: B cell defect Humoral: Complement Cellular: T cells Combined severe immunodeficiency Secondary
More informationReceived 1 July 2004/Returned for modification 23 August 2004/Accepted 6 October 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 606 611 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.606 611.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationAcyclovir for ear infections
Acyclovir for ear infections The Borg System is 100 % Acyclovir for ear infections User feedback about Acyclovir side effects covering chicken pox, fatigue, shingles, hair loss, HSV2, dosage, anemia, ear
More information½ of all new infections are among people aged although this age group represents <25% of the sexually experienced population.
Impact Almost 20 million - newly diagnosed STD s/sti s each year. $16 billion cost of treating STI s ½ of all new infections are among people aged 15-24 although this age group represents
More informationA systematic review of evidence-based guidelines for drug therapies for viral encephalitis in children
DOI:10.16636/j.cnki.jinn.2015.06.007 2 015 4 2 6 1 1 1 2 1 1. 530021 2. 530021 PubMed EMbase CBM CNKI NGC GIN TRIP CDC IDSA AAP WHO 2014 10 2 Ⅱ AGREEⅡ ICC 3 5 B AGREEⅡ6 68. 54 % Ⅱ A systematic review of
More informationLRI Children s Hospital. Management of chicken pox exposure in paediatrics
LRI Children s Hospital Management of chicken pox exposure in paediatrics Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team approval date: October 018 Version: V 3 Revision
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION July 18, 2007 ZELITREX 500 mg coated tablet Packs of 10 tablets (CIP: 341 708-3) ZELITREX 500 mg coated tablet: Pack
More informationGanciclovir-resistant CMV retinitis in a patient with wild-type plasma CMV. North Carolina School of Medicine, Chapel Hill, NC
JCM Accepts, published online ahead of print on 15 February 2012 J. Clin. Microbiol. doi:10.1128/jcm.00029-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Ganciclovir-resistant
More informationCondition: Herpes Simplex Keratitis
Condition: Herpes Simplex Keratitis Description: Herpes simplex infection is very common but usually remains latent. When the virus is reactivated it travels along the trigeminal nerve to cause local infection
More informationAdvances in gene encoding proteins of human herpesvirus 6
2009 9 4 3 Journal of Microbes and Infection, September 2009, Vol. 4, No. 3 165 6 1, 2 1., 241000; 2., 210029 : 6 ( HHV-6) DNA, HHV-6 80 100, ( IE) DNA DNA HHV-6 : 6 ; ; Advances in gene encoding proteins
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationJMSCR Volume 03 Issue 01 Page January 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Seroprevalence of HBV among HIV Patients and Blood Donors Author Dr. Vedavati B I 1, Dr. Amrutha Kumari B 2, Dr. Venkatesha D 3 Mysore
More informationWelcome to Pathogen Group 6
Welcome to Pathogen Group 6 Human herpesviruses 1 (HHV-1) and 2 (HHV-2 or HSV-2) Varicella-zoster virus (chickenpox and shingles) Neisseria gonorrhoeae Treponema pallidum Human papillomaviruses (HPV) Human
More informationHerpes virus co-factors in HIV infection
Herpes virus co-factors in HIV infection Dr Jane Deayton Barts and the London Queen Mary School of Medicine Introduction Herpes viruses very common and often coexist with HIV Establish life-long latent
More information*viruses have no cell wall and made up of nucleic acid components.
Anti-viral drugs {Please read these notes together with the slides since I only wrote what the doctor added} Apologies in advance for any mistakes In this sheet we are going to talk about anti-viral drugs,
More informationPAEDIATRIC ACUTE CARE GUIDELINE. Herpes Stomatitis
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Herpes Stomatitis Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read
More informationCurriculum vitae. PD Dr. med. Georg Werner Feldmann
Curriculum vitae Personal data: Name: Nationality: Familial status: PD Dr. med. Georg Werner Feldmann German married Business Address: Department of Internal Medicine 3 Center of Integrated Oncology (CIO)
More informationCase Report Disseminated Herpes Simplex Virus with Fulminant Hepatitis
Case Reports in Hepatology Volume 2015, Article ID 463825, 4 pages http://dx.doi.org/10.1155/2015/463825 Case Report Disseminated Herpes Simplex Virus with Fulminant Hepatitis Bassam H. Rimawi, 1 Joseph
More informationHerpes zoster. Diagnosis, Complications, Treatment, Prevention 서울대학교병원 FM R2 임하연
Herpes zoster Diagnosis, Complications, Treatment, Prevention 2018.04.14 서울대학교병원 FM R2 임하연 1 2 Overview reactivation of lat ent VZV along sensory nerve VZV(varicella-zoster virus) Human herpes virus-3
More informationStudy group SBS-AE. Version
Study group SBS-AE a. Dipl.-Psych. Michael Köhler E-Mail: michael.koehler@med.ovgu.de Investigators a. Prof. Dr. med. Thomas Fischer E-Mail: thomas.fischer@med.ovgu.de a. Prof. Dr. med. Jörg Frommer, M.A.
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationFlu Vaccination. John Hann, MD UC Irvine Health
Flu Vaccination John Hann, MD UC Irvine Health So you got the flu. What to do about. Influenza spread in US https://www.cdc.gov/flu/weekly/ Influenza spread world wide http://apps.who.int/flumart/default?reportno=6
More informationHIV/AIDS & Immune Evasion Strategies. The Year First Encounter: Dr. Michael Gottleib. Micro 320: Infectious Disease & Defense
Micro 320: Infectious Disease & Defense HIV/AIDS & Immune Evasion Strategies Wilmore Webley Dept. of Microbiology The Year 1981 Reported by MS Gottlieb, MD, HM Schanker, MD, PT Fan, MD, A Saxon, MD, JD
More informationSTIs- REVISION. Prof A A Hoosen
STIs- REVISION Prof A A Hoosen Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria and the NHLS Microbiology Tertiary Laboratory at the Pretoria Academic Hospital Complex
More informationKombination von Checkpointinhibitoren beim malignen Melanom
Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom
More informationHepatitis B Virus infection: virology
Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department
More informationTrial record 1 of 1 for:
This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationSusceptibility of Herpes Simplex Virus Isolated from Genital Herpes Lesions to ASP2151, A
AAC Accepts, published online ahead of print on 23 April 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.00133-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Susceptibility
More informationESCMID Postgraduate Education Course Infectious Diseases in Pregnant Women, Fetuses and Newborns Bertinoro, Italy 3 7 October 2010
ESCMID Postgraduate Education Course Infectious Diseases in Pregnant Women, Fetuses and Newborns Bertinoro, Italy 3 7 October 2010 Robert Pass University of Alabama at Birmingham School of Medicine Disclosures:
More informationTransmission of HEV by plasmapheresis. Vincent Mallet, MD, PhD CHU Cochin, Université Paris Descartes, APHP, Inserm
Transmission of HEV by plasmapheresis Vincent Mallet, MD, PhD CHU Cochin, Université Paris Descartes, APHP, Inserm Transmission of HEV by secured plasma Transmission of HEV by plasma IA Transmission of
More informationFACT SHEET FOR ADDITIONAL INFORMATION CONTACT
FACT SHEET FOR ADDITIONAL INFORMATION CONTACT Caroline Calderone Baisley, MPH, RS Michael S. Long, MS Director of Health Director of Environmental Services Tel. 203-622-7836 Tel: 203-622-7838 SMALLPOX:
More information-738 proteins were found only in the ME subjects proteins were only found in PTLS samples proteins were only found in the normal controls.
RECENT RESEARCH Currently there is much exciting research being published including the Schutzer et al. study that compared cerebrospinal fluid proteomes to differentiate ME and Post Treatment Lyme Syndrome
More informationIt has been estimated that 90% of individuals
Famciclovir for Cutaneous Herpesvirus Infections: An Update and Review of New Single-Day Dosing Indications Manju Chacko, MD; Jeffrey M. Weinberg, MD Infections with herpes simplex virus (HSV) types 1
More informationAnti-viral drugs. Certain viruses multiply in the cytoplasm but others do in the nucleus Most multiplication take place before diagnosis is made
Anti-viral Drugs Viruses have no cell wall and made up of nucleic acid components Viruses containing envelope antigenic in nature Viruses are obligate intracellular parasite They do not have a metabolic
More informationGuidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT)
Guidelines for immunisation of children following treatment with high dose chemotherapy and Haematopoietic Stem Cell Transplantation (HSCT) Version 2.0 Approved by Haem / Onc Senior Clinical Management
More informationINTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION a Society that includes Basic Science, the Failing Heart, and Advanced Lung Disease
International Society of Heart and Lung Transplantation Advisory Statement on the Implications of Pandemic Influenza for Thoracic Organ Transplantation This advisory statement has been produced by the
More informationBRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS
BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS Diana F. Florescu, MD 1, Michael S. Grimley, MD 2, Genovefa
More informationAntiviral treatment for shingles and its complications in immunocompetent adults
Quality Improvement Scotland In response to an enquiry from NHS Greater Glasgow & Clyde Number 21 January 2008 Antiviral treatment for shingles and its complications in immunocompetent adults Description
More informationCURRICULUM VITAE Shahla Z. Abghari
Shahla Z. Abghari, Ph. D. Updated March 4, 2014 PAGE 1 CURRICULUM VITAE Shahla Z. Abghari U. S. CITIZENSHIP: April 1992 EDUCATION: 1966-1970 B.S., Biology, Teachers University, Tehran, Iran 1967-1971 B.A.,
More informationDiagnosis of Viral Infections. Antiviral Agents. Herpes Zoster. Challenges to the Development of Effective Antiviral Agents
Diagnosis of Viral Infections Antiviral Agents Scott M. Hammer, M.D. Clinical suspicion Is syndrome diagnostic of a specific entity? Is viral disease in the differential diagnosis of a presenting syndrome?
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationProperties of Herpesviruses
Herpesviruses Properties of Herpesviruses Structure and Composition Spherical icosahedron, 150-200 nm Double-stranded DNA, linear More than 35 proteins Enveloped Replication from nucleus (budding) Features
More informationCommon Features of Herpesviruses
Common Features of Herpesviruses Morphology Basic mode of replication Primary infection followed by latency Ubiquitous Ability to cause recurrent infections (reactivation of latent virus), reinfections
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationMID 40. Diagnosis of Viral Infections. Antiviral Therapy. Herpes Zoster. Challenges to the Development of Effective Antiviral Agents
Diagnosis of Viral Infections Antiviral Therapy Scott M. Hammer, M.D. Clinical suspicion Is syndrome diagnostic of a specific entity? Is viral disease in the differential diagnosis of a presenting syndrome?
More informationHuman Herpesviruses. Varicella-zoster virus. Human Herpesvirus (VZV) phospholipid envelope, tegument, icosahedral capsid, DNA core
Common Features of Herpesviruses Morphology Basic mode of replication Primary infection followed by latency Ubiquitous Human Herpesvirus (VZV) phospholipid envelope, tegument, icosahedral capsid, DNA core
More informationEyeGene Inc. Contact Information Korea Health Industry Development Institute
EG-Mirotin: First-in-Class recombinant polypeptide novel subcutaneous drug containing RGD-motif targeted to suppress edema and vascular leakage for Nonproliferative Diabetic Retinopathy (NPDR) EyeGene
More informationJP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019
JP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking
More informationFor more information about how to cite these materials visit
Author(s): David Miller, M.D., Ph.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationUnited Nations General Assembly June 8, 2011
Remarks by Dr. Mathilde Krim United Nations General Assembly June 8, 2011 I am Mathilde Krim, the Founding Chairman of amfar, The Foundation for AIDS Research. This is a not-for-profit foundation based
More informationMichael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4
Twice-weekly Brincidofovir (BCV, CMX1) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia Michael Grimley 1, Vinod Prasad, Joanne Kurtzberg,
More informationAntiviral Agents. Scott M. Hammer, M.D. Challenges to the Development of Effective Antiviral Agents
Antiviral Agents Scott M. Hammer, M.D. Challenges to the Development of Effective Antiviral Agents Myriad number of agents Need knowledge of replication at molecular level to define targets Viruses as
More informationVaricella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus
Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus Helena M. Tabery Varicella-Zoster Virus Epithelial Keratitis in Herpes Zoster Ophthalmicus In Vivo Morphology in the Human Cornea
More informationMarmoset-based infectious disease research under biocontainment conditions
Marmoset-based infectious disease research under biocontainment conditions Jean Patterson, PhD Texas Biomedical Research Institute October 22 nd, 2018 West Nile virus Common marmoset found to be equivalently
More informationImage of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
More informationReceived 5 December 2003; accepted 21 January 2004
Journal of Antimicrobial Chemotherapy (2004) 53, 703 707 DOI: 10.1093/jac/dkh154 Advance Access publication 24 March 2004 Clinical significance of antiviral therapy for episodic treatment of herpes labialis:
More informationGSK s Adjuvanted Influenza Vaccines The Taming of the Flu
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu JITMM, Bangkok, October 2008 Bruce L. Innis, MD Global Clinical Research and Development GlaxoSmithKline Biologicals 1 Annual Burden of Influenza
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive
More informationLIVING WITH HEPATITIS B
LIVING WITH HEPATITIS B Welcome What is hep B? Hepatitis B (or hep B) is a serious liver disease that affects millions of people across the world. This brochure is here to help you better understand hep
More informationChildhood corneal neovascularization
Miltos Balidis PhD, FEBOphth, ICOphth Sotiria Palioura MD,PhD Childhood corneal neovascularization Opacities Cornea clarity is essential for optimal vision at any age. In childhood, loss of corneal transparency
More informationSeasonal Influenza. Provider Information Sheet. Infectious Disease Epidemiology Program
August 2007 te: This sheet contains information on seasonal influenza. For information on avian or pandemic influenza, contact the (800-423-1271 or 304-558-5358). What is influenza-like illness (ILI)?
More information